Literature DB >> 29948250

The cognitive, affective motivational and clinical longitudinal determinants of apathy in schizophrenia.

Stéphane Raffard1,2, Catherine Bortolon3,4, Hanan Yazbek3,4, Christophe Lançon5, Michel Benoit6, Joanna Norton7,8, Delphine Capdevielle3,7,8.   

Abstract

Apathy is a frequent and debilitating condition with few treatment options available in schizophrenia patients. Despite evidence of its multidimensional structure, most of past studies have explored apathy through a categorical approach. The main objective of this study was to identify the cognitive, emotional, motivational, and clinical factors at baseline that best predicted the three subtypes of apathy dimensions at follow-up. In a longitudinal study, 137 participants diagnosed with schizophrenia underwent different assessments including clinical, motivational, affective and cognitive measurements, at 1-month (referred to as baseline) and 12-month follow-ups. Data were analyzed using partial least squares variance-based structural equation modeling. Three latent variables representing the three previously described domains of apathy reaching consensus in the literature were extracted from the Lille Apathy Rating Scale. Results showed that in addition to baseline apathy, positive symptoms, anticipatory pleasure and sensibility to punishment at baseline predicted cognitive apathy at follow-up. Likewise, both baseline apathy and sensibility to punishment predicted emotional apathy at follow-up. Finally, baseline anhedonia and episodic memory were the main variables the predicted behavioral apathy at follow-up. This is the first study to show specific associations between apathy subtypes and clinical and cognitive motivational dysfunction in individual with schizophrenia, indicating possible distinct underlying mechanisms to these demotivational symptoms. Treatment for apathy should address both types of processes. Importantly, our results demonstrate the interest of multidimensional approaches in the understanding of apathy in schizophrenia.

Entities:  

Keywords:  Apathy; Longitudinal study; Negative symptoms; Partial least squares-path modeling

Mesh:

Year:  2018        PMID: 29948250     DOI: 10.1007/s00406-018-0907-1

Source DB:  PubMed          Journal:  Eur Arch Psychiatry Clin Neurosci        ISSN: 0940-1334            Impact factor:   5.270


  56 in total

Review 1.  A new perspective on anhedonia in schizophrenia.

Authors:  Gregory P Strauss; James M Gold
Journal:  Am J Psychiatry       Date:  2012-04       Impact factor: 18.112

Review 2.  Apathy and the functional anatomy of the prefrontal cortex-basal ganglia circuits.

Authors:  Richard Levy; Bruno Dubois
Journal:  Cereb Cortex       Date:  2005-10-05       Impact factor: 5.357

3.  Covariance of positive and negative symptoms during neuroleptic treatment in schizophrenia: a replication.

Authors:  R Tandon; S C Ribeiro; J R DeQuardo; R S Goldman; J Goodson; J F Greden
Journal:  Biol Psychiatry       Date:  1993-10-01       Impact factor: 13.382

Review 4.  [The clinic of apathy in schizophrenia: a critical review of the issue].

Authors:  H Yazbek; S Raffard; J Del-Monte; F Pupier; A Larue; J-P Boulenger; M-C Gély-Nargeot; D Capdevielle
Journal:  Encephale       Date:  2013-08-16       Impact factor: 1.291

5.  Motivation and Social Cognition in Patients with Schizophrenia.

Authors:  Gagan Fervaha; Ishraq Siddiqui; George Foussias; Ofer Agid; Gary Remington
Journal:  J Int Neuropsychol Soc       Date:  2015-07-02       Impact factor: 2.892

6.  Diagnostic criteria for apathy in clinical practice.

Authors:  E Mulin; E Leone; K Dujardin; M Delliaux; A Leentjens; F Nobili; B Dessi; O Tible; L Agüera-Ortiz; R S Osorio; J Yessavage; D Dachevsky; F R J Verhey; Alfonso J Cruz Jentoft; O Blanc; P M Llorca; P H Robert
Journal:  Int J Geriatr Psychiatry       Date:  2011-02       Impact factor: 3.485

7.  A review of reward processing and motivational impairment in schizophrenia.

Authors:  Gregory P Strauss; James A Waltz; James M Gold
Journal:  Schizophr Bull       Date:  2013-12-27       Impact factor: 9.306

8.  Treatments of Negative Symptoms in Schizophrenia: Meta-Analysis of 168 Randomized Placebo-Controlled Trials.

Authors:  Paolo Fusar-Poli; Evangelos Papanastasiou; Daniel Stahl; Matteo Rocchetti; William Carpenter; Sukhwinder Shergill; Philip McGuire
Journal:  Schizophr Bull       Date:  2014-12-20       Impact factor: 9.306

9.  An early Phase II randomised controlled trial testing the effect on persecutory delusions of using CBT to reduce negative cognitions about the self: the potential benefits of enhancing self confidence.

Authors:  Daniel Freeman; Katherine Pugh; Graham Dunn; Nicole Evans; Bryony Sheaves; Felicity Waite; Emma Cernis; Rachel Lister; David Fowler
Journal:  Schizophr Res       Date:  2014-11-11       Impact factor: 4.939

10.  Substantia nigra/ventral tegmental reward prediction error disruption in psychosis.

Authors:  G K Murray; P R Corlett; L Clark; M Pessiglione; A D Blackwell; G Honey; P B Jones; E T Bullmore; T W Robbins; P C Fletcher
Journal:  Mol Psychiatry       Date:  2007-08-07       Impact factor: 15.992

View more
  1 in total

1.  From Memories of Past Experiences to Present Motivation? A Meta-analysis on the Association Between Episodic Memory and Negative Symptoms in People With Psychosis.

Authors:  Matthias Pillny; Katarina Krkovic; Laura Buck; Tania M Lincoln
Journal:  Schizophr Bull       Date:  2022-03-01       Impact factor: 7.348

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.